ABIVAX SA (2X1.DE) Fundamental Analysis & Valuation

FRA:2X1 • FR0012333284

Current stock price

95.4 EUR
-1.1 (-1.14%)
Last:

This 2X1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. 2X1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year 2X1 has reported negative net income.
  • 2X1 had a negative operating cash flow in the past year.
  • In the past 5 years 2X1 always reported negative net income.
  • 2X1 had a negative operating cash flow in each of the past 5 years.
2X1.DE Yearly Net Income VS EBIT VS OCF VS FCF2X1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • The Return On Assets of 2X1 (-57.52%) is worse than 70.83% of its industry peers.
  • 2X1 has a Return On Equity (-73.84%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -57.52%
ROE -73.84%
ROIC N/A
ROA(3y)-62.86%
ROA(5y)-61.29%
ROE(3y)-194.49%
ROE(5y)-314.42%
ROIC(3y)N/A
ROIC(5y)N/A
2X1.DE Yearly ROA, ROE, ROIC2X1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for 2X1 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2X1.DE Yearly Profit, Operating, Gross Margins2X1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. 2X1.DE Health Analysis

2.1 Basic Checks

  • 2X1 has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for 2X1 has been increased compared to 5 years ago.
  • 2X1 has a better debt/assets ratio than last year.
2X1.DE Yearly Shares Outstanding2X1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
2X1.DE Yearly Total Debt VS Total Assets2X1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 32.99 indicates that 2X1 is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 32.99, 2X1 belongs to the best of the industry, outperforming 98.61% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that 2X1 is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.00, 2X1 belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 32.99
ROIC/WACCN/A
WACCN/A
2X1.DE Yearly LT Debt VS Equity VS FCF2X1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 8.75 indicates that 2X1 has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 8.75, 2X1 belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
  • 2X1 has a Quick Ratio of 8.75. This indicates that 2X1 is financially healthy and has no problem in meeting its short term obligations.
  • 2X1 has a Quick ratio of 8.75. This is amongst the best in the industry. 2X1 outperforms 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 8.75
Quick Ratio 8.75
2X1.DE Yearly Current Assets VS Current Liabilites2X1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. 2X1.DE Growth Analysis

3.1 Past

  • The earnings per share for 2X1 have decreased strongly by -72.93% in the last year.
EPS 1Y (TTM)-72.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-116%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-55.93%

3.2 Future

  • The Earnings Per Share is expected to grow by 24.94% on average over the next years. This is a very strong growth
  • 2X1 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 183.39% yearly.
EPS Next Y81.52%
EPS Next 2Y6.92%
EPS Next 3Y23.89%
EPS Next 5Y24.94%
Revenue Next Year-10.7%
Revenue Next 2Y514.77%
Revenue Next 3Y428.14%
Revenue Next 5Y183.39%

3.3 Evolution

2X1.DE Yearly Revenue VS Estimates2X1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
2X1.DE Yearly EPS VS Estimates2X1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. 2X1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • 2X1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year 2X1 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
2X1.DE Price Earnings VS Forward Price Earnings2X1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
2X1.DE Per share data2X1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as 2X1's earnings are expected to grow with 23.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.92%
EPS Next 3Y23.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 2X1.DE Dividend Analysis

5.1 Amount

  • No dividends for 2X1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

2X1.DE Fundamentals: All Metrics, Ratios and Statistics

ABIVAX SA

FRA:2X1 (4/28/2026, 7:00:00 PM)

95.4

-1.1 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength40.54
Industry Growth78
Earnings (Last)03-23
Earnings (Next)05-25
Inst Owners37.95%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.56B
Revenue(TTM)N/A
Net Income(TTM)-336.10M
Analysts85.71
Price Target132.47 (38.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.47%
PT rev (3m)11.51%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-10.89%
Revenue NY rev (3m)-14.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 16.62
P/tB 17.58
EV/EBITDA N/A
EPS(TTM)-4.83
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0
BVpS5.74
TBVpS5.43
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -57.52%
ROE -73.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.86%
ROA(5y)-61.29%
ROE(3y)-194.49%
ROE(5y)-314.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.75
Quick Ratio 8.75
Altman-Z 32.99
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)44.47%
Cap/Depr(5y)46.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-116%
EPS Next Y81.52%
EPS Next 2Y6.92%
EPS Next 3Y23.89%
EPS Next 5Y24.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-55.93%
Revenue Next Year-10.7%
Revenue Next 2Y514.77%
Revenue Next 3Y428.14%
Revenue Next 5Y183.39%
EBIT growth 1Y-42.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.18%
EBIT Next 3Y69.97%
EBIT Next 5YN/A
FCF growth 1Y37.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.96%
OCF growth 3YN/A
OCF growth 5YN/A

ABIVAX SA / 2X1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ABIVAX SA (2X1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to 2X1.DE.


What is the valuation status for 2X1 stock?

ChartMill assigns a valuation rating of 1 / 10 to ABIVAX SA (2X1.DE). This can be considered as Overvalued.


How profitable is ABIVAX SA (2X1.DE) stock?

ABIVAX SA (2X1.DE) has a profitability rating of 0 / 10.


What is the expected EPS growth for ABIVAX SA (2X1.DE) stock?

The Earnings per Share (EPS) of ABIVAX SA (2X1.DE) is expected to grow by 81.52% in the next year.